首页 > 最新文献

Doklady Biochemistry and Biophysics最新文献

英文 中文
Pharmacological Modulation of Cognitive Test Solution in Mice of Two Genotypes. 药物调节两种基因型小鼠的认知测试方案
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924701096
O V Perepelkina, I I Poletaeva

Mice of two strains selected for successful solution of "object permanence" test and for lack of such solution demonstrated the differential reaction to injections of two drugs. The effects of injections of atomoxetine. which blocks the noradrenaline reuptake, and of 'non-benzodiazepine" anxiolytic afobazol was different. The success of solutions increased in mice selected for this test "non-solution": and decreased or was inefficient in mice, selected for successful solution of object permanence cognitive test.

成功通过 "物体永存 "测试和未通过该测试的两个品系的小鼠对注射两种药物的反应不同。注射阻断去甲肾上腺素再摄取的阿托西汀和 "非苯二氮卓 "抗焦虑药阿福巴唑的效果是不同的。被选中进行 "无解 "测试的小鼠的解题成功率提高了:而被选中进行物体永存认知测试的小鼠的解题成功率降低或效率低下。
{"title":"Pharmacological Modulation of Cognitive Test Solution in Mice of Two Genotypes.","authors":"O V Perepelkina, I I Poletaeva","doi":"10.1134/S1607672924701096","DOIUrl":"https://doi.org/10.1134/S1607672924701096","url":null,"abstract":"<p><p>Mice of two strains selected for successful solution of \"object permanence\" test and for lack of such solution demonstrated the differential reaction to injections of two drugs. The effects of injections of atomoxetine. which blocks the noradrenaline reuptake, and of 'non-benzodiazepine\" anxiolytic afobazol was different. The success of solutions increased in mice selected for this test \"non-solution\": and decreased or was inefficient in mice, selected for successful solution of object permanence cognitive test.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary Study on Polymerization between Hemoglobin and Enzymes during the Preparation of PolyHb-SOD-CAT-CA. 制备 PolyHb-SOD-CAT-CA 过程中血红蛋白与酶之间聚合作用的初步研究
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600477
Lili Zhang, Renci Tian, Jiawei Xiao, Yaoxi Wang, Kun Feng, Gang Chen

The objective of this study was to explore the influence of different factors on the aggregation effect on hemoglobin (Hb) and enzymes during the preparation of Polyhemoglobin-Superoxide dismutase-Catalase-Carbonic anhydrase (PolyHb-SOD-CAT-CA). Several factors including temperatures, pH values, Glutaraldehyde (GDA) amounts and enzymes amounts were investigated systematically to study their effects on the enzymes recoveries and polymerization rates including the Superoxide dismutase (SOD), Catalase (CAT) and Carbonic anhydrase (CA), as well as their effects on the molecular weight distribution of PolyHb-SOD-CAT-CA. Then the oxygen affinity and methemoglobin (MetHb) contents of obtained PolyHb-SOD-CAT-CA were measured to evaluate the effects of enzyme crosslinking on the properties of Polyhemoglobin (PolyHb) moieties in the molecular structure of obtained PolyHb-SOD-CAT-CA conjugate. The results showed that the enzyme recoveries and polymerization rates could be decreased with the temperatures increasing and could be generally kept stable in the physiological pH conditions, but presented only slight changes among the investigated enzyme amounts ranges. Although the GDA concentration increasing could promote the enzyme polymerization rates, the enzyme recoveries decreased in whole. The polymerization rate and molecular size of PolyHb-SOD-CAT-CA conjugate increased with the elevation of temperature and the concentration of GDA. Lastly, the P50 values, Hill coefficients, and MetHb contents of PolyHb-SOD-CAT-CA conjugate with different enzyme crosslinking degrees exhibited no obvious differences with each other. In conclusion, the polymerization reactions between enzymes and Hb molecules could be remarkably affected by temperatures, pH values, and GDA amounts, and the enzyme crosslinking presented no obvious effects on the Hb properties, especially about the oxygen affinity and oxidation degrees.

本研究旨在探讨在制备聚血红蛋白-超氧化物歧化酶-催化酶-碳酸酐酶(PolyHb-SOD-CAT-CA)的过程中,不同因素对血红蛋白(Hb)和酶的聚集效应的影响。研究人员系统地考察了温度、pH 值、戊二醛(GDA)用量和酶用量等因素对超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和碳酸酐酶(CA)等酶的回收率和聚合率的影响,以及它们对聚合血红蛋白-超氧化物歧化酶-过氧化氢酶-碳酸酐酶(PolyHb-SOD-CAT-CA)分子量分布的影响。然后测定了所得 PolyHb-SOD-CAT-CA 的氧亲和力和高铁血红蛋白(MetHb)含量,以评估酶交联对所得 PolyHb-SOD-CAT-CA 共轭物分子结构中高铁血红蛋白(PolyHb)分子性能的影响。结果表明,酶的回收率和聚合率会随着温度的升高而降低,在生理 pH 条件下基本保持稳定,但在所研究的酶用量范围内变化不大。虽然 GDA 浓度的增加会促进酶的聚合速率,但酶的回收率却整体下降。随着温度和 GDA 浓度的升高,PolyHb-SOD-CAT-CA 共轭物的聚合速率和分子大小都有所增加。最后,不同酶交联度的 PolyHb-SOD-CAT-CA 共轭物的 P50 值、希尔系数和 MetHb 含量均无明显差异。总之,酶与 Hb 分子的聚合反应会受到温度、pH 值和 GDA 含量的显著影响,而酶交联对 Hb 性能,尤其是氧亲和性和氧化度没有明显影响。
{"title":"Preliminary Study on Polymerization between Hemoglobin and Enzymes during the Preparation of PolyHb-SOD-CAT-CA.","authors":"Lili Zhang, Renci Tian, Jiawei Xiao, Yaoxi Wang, Kun Feng, Gang Chen","doi":"10.1134/S1607672924600477","DOIUrl":"https://doi.org/10.1134/S1607672924600477","url":null,"abstract":"<p><p>The objective of this study was to explore the influence of different factors on the aggregation effect on hemoglobin (Hb) and enzymes during the preparation of Polyhemoglobin-Superoxide dismutase-Catalase-Carbonic anhydrase (PolyHb-SOD-CAT-CA). Several factors including temperatures, pH values, Glutaraldehyde (GDA) amounts and enzymes amounts were investigated systematically to study their effects on the enzymes recoveries and polymerization rates including the Superoxide dismutase (SOD), Catalase (CAT) and Carbonic anhydrase (CA), as well as their effects on the molecular weight distribution of PolyHb-SOD-CAT-CA. Then the oxygen affinity and methemoglobin (MetHb) contents of obtained PolyHb-SOD-CAT-CA were measured to evaluate the effects of enzyme crosslinking on the properties of Polyhemoglobin (PolyHb) moieties in the molecular structure of obtained PolyHb-SOD-CAT-CA conjugate. The results showed that the enzyme recoveries and polymerization rates could be decreased with the temperatures increasing and could be generally kept stable in the physiological pH conditions, but presented only slight changes among the investigated enzyme amounts ranges. Although the GDA concentration increasing could promote the enzyme polymerization rates, the enzyme recoveries decreased in whole. The polymerization rate and molecular size of PolyHb-SOD-CAT-CA conjugate increased with the elevation of temperature and the concentration of GDA. Lastly, the P50 values, Hill coefficients, and MetHb contents of PolyHb-SOD-CAT-CA conjugate with different enzyme crosslinking degrees exhibited no obvious differences with each other. In conclusion, the polymerization reactions between enzymes and Hb molecules could be remarkably affected by temperatures, pH values, and GDA amounts, and the enzyme crosslinking presented no obvious effects on the Hb properties, especially about the oxygen affinity and oxidation degrees.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Protective Effect of Umbelliferone on Acute Kidney Injury in Rats via Alteration of HO-1/Nrf2 and NF-κB Signaling Pathway. 伞形酮通过改变 HO-1/Nrf2 和 NF-κB 信号通路对大鼠急性肾损伤的肾保护作用
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S160767292460043X
RuiJuan Yan, Hui Yang, XiaoQi Jiang, XiaoDong Lai

Acute kidney injury (AKI), formerly known as acute renal failure, refers to a sudden and often reversible decline in kidney function. Inflammatory reaction and oxidative stress play a crucial role in the expansion of renal disease. In this experimental study, we scrutinized the renal protective effect of umbelliferone against gentamicin induced renal injury in the rats and explore the mechanism. Wistar rats were used in this study and Gentamicin was used for the induction the AKI in the rats and rats were received the oral administration of umbelliferone. The body weight, organ weight, renal, oxidative stress, cytokines, inflammatory parameters were estimated. The mRNA expression caspase-3, Bax, Bcl-2, TNF-α, IL-1β, IL-6, IL-10, HO-1, and Nrf2 were estimated. Umbelliferone remarkably improved the body weight and altered the absolute and relative weight of hepatic and renal tissue. Umbelliferone significantly suppressed the level of BUN, Scr, magnesium, calcium, phosphorus, sodium, and potassium along with altered the level of oxidative stress parameters like CAT, SOD, GSH, LPO, and GPx. Umbelliferone altered the level of cytokines viz., TNF-α, Il-1β, IL-6, IL-10; inflammatory parameters like PGE2, COX-2, TGF-β, NF-κB, respectively. Umbelliferone significantly altered the mRNA expression of caspase-3, Bax, Bcl-2, TNF-α, IL-1β, IL-6, IL-10, HO-1, and Nrf2. The result showed the renal protective effect of umbelliferone against gentamycin induced renal disease via alteration of HO-1/Nrf2 and NF-κB Signaling Pathway.

急性肾损伤(AKI),以前称为急性肾衰竭,是指肾功能突然下降,而且往往是可逆的。炎症反应和氧化应激在肾脏疾病的扩展中起着至关重要的作用。在这项实验研究中,我们仔细研究了伞形酮对庆大霉素诱导的大鼠肾损伤的保护作用,并探讨了其机制。本研究使用 Wistar 大鼠,用庆大霉素诱导大鼠发生 AKI,并给大鼠口服脐叶素。对大鼠的体重、器官重量、肾脏、氧化应激、细胞因子和炎症指标进行了估计。此外,还估测了 caspase-3、Bax、Bcl-2、TNF-α、IL-1β、IL-6、IL-10、HO-1 和 Nrf2 的 mRNA 表达。伞形酮显著改善了体重,改变了肝脏和肾脏组织的绝对和相对重量。伞形酮明显抑制了 BUN、Scr、镁、钙、磷、钠和钾的水平,并改变了 CAT、SOD、GSH、LPO 和 GPx 等氧化应激参数的水平。伞形酮分别改变了细胞因子的水平,即 TNF-α、Il-1β、IL-6、IL-10;炎症参数,如 PGE2、COX-2、TGF-β、NF-κB。伞形酮明显改变了caspase-3、Bax、Bcl-2、TNF-α、IL-1β、IL-6、IL-10、HO-1和Nrf2的mRNA表达。结果表明,伞形酮通过改变HO-1/Nrf2和NF-κB信号通路对庆大霉素诱导的肾病有保护作用。
{"title":"Renal Protective Effect of Umbelliferone on Acute Kidney Injury in Rats via Alteration of HO-1/Nrf2 and NF-κB Signaling Pathway.","authors":"RuiJuan Yan, Hui Yang, XiaoQi Jiang, XiaoDong Lai","doi":"10.1134/S160767292460043X","DOIUrl":"https://doi.org/10.1134/S160767292460043X","url":null,"abstract":"<p><p>Acute kidney injury (AKI), formerly known as acute renal failure, refers to a sudden and often reversible decline in kidney function. Inflammatory reaction and oxidative stress play a crucial role in the expansion of renal disease. In this experimental study, we scrutinized the renal protective effect of umbelliferone against gentamicin induced renal injury in the rats and explore the mechanism. Wistar rats were used in this study and Gentamicin was used for the induction the AKI in the rats and rats were received the oral administration of umbelliferone. The body weight, organ weight, renal, oxidative stress, cytokines, inflammatory parameters were estimated. The mRNA expression caspase-3, Bax, Bcl-2, TNF-α, IL-1β, IL-6, IL-10, HO-1, and Nrf2 were estimated. Umbelliferone remarkably improved the body weight and altered the absolute and relative weight of hepatic and renal tissue. Umbelliferone significantly suppressed the level of BUN, Scr, magnesium, calcium, phosphorus, sodium, and potassium along with altered the level of oxidative stress parameters like CAT, SOD, GSH, LPO, and GPx. Umbelliferone altered the level of cytokines viz., TNF-α, Il-1β, IL-6, IL-10; inflammatory parameters like PGE2, COX-2, TGF-β, NF-κB, respectively. Umbelliferone significantly altered the mRNA expression of caspase-3, Bax, Bcl-2, TNF-α, IL-1β, IL-6, IL-10, HO-1, and Nrf2. The result showed the renal protective effect of umbelliferone against gentamycin induced renal disease via alteration of HO-1/Nrf2 and NF-κB Signaling Pathway.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term GABA Supplementation Regulates Diabetic Gastroenteropathy through GABA Receptor/trypsin-1/PARs/Akt/COX-2 Axis. 长期补充 GABA 可通过 GABA 受体/胰蛋白酶-1/PARs/Akt/COX-2 轴调节糖尿病胃肠病。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600386
Farzaneh Yazdanimoghaddam, Hossein Rezazadeh, Nepton Soltani, Nasrin Mehranfard, Azadesadat Hosseini Dastgerdi, Mahtab Ghanbari Rad, Maedeh Ghasemi

Aim: Molecular alterations of diabetic gastroenteropathy are poorly identified. This study investigates the effects of prolonged GABA supplementation on key protein expression levels of trypsin-1, PAR-1, PAR-2, PAR-3, PI3K, Akt, COX-2, GABAA, and GABAB receptors in the gastric tissue of type 2 diabetic rats (T2DM).

Method: -To induce T2DM, a 3-month high-fat diet and 35 mg/kg of streptozotocin was used. Twenty-four male Wistar rats were divided into 4 groups: (1) control, (2) T2DM, (3) insulin-treated (2.5 U/kg), and (4) GABA-treated (1.5 g/kg GABA). Blood glucose was measured weekly. The protein expressions were assessed using western blotting. Histopathological changes were examined by H&E and Masson's staining.

Results: -Diabetic rats show reduced NOS1 and elevated COX-2 and trypsin-1 protein expression levels in gastric tissue. Insulin and GABA therapy restored the NOS1 and COX-2 levels to control values. Insulin treatment increased PI3K, Akt, and p-Akt and, decreased trypsin-1, PAR-1, PAR-2, and PAR-3 levels in the diabetic rats. Levels of GABAA and GABAB receptors normalized following insulin and GABA therapy. H&E staining indicated an increase in mucin secretion following GABA treatment.

Conclusion: -These results suggest that GABA by acting on GABA receptors may regulate the trypsin-1/PARs/Akt/COX-2 pathway and thereby improve complications of diabetic gastroenteropathy.

目的:糖尿病胃肠病的分子改变尚未被明确。本研究探讨了长期补充 GABA 对 2 型糖尿病大鼠(T2DM)胃组织中胰蛋白酶-1、PAR-1、PAR-2、PAR-3、PI3K、Akt、COX-2、GABAA 和 GABAB 受体的关键蛋白表达水平的影响。将 24 只雄性 Wistar 大鼠分为 4 组:(1) 对照组;(2) T2DM 组;(3) 胰岛素处理组(2.5 U/kg);(4) GABA 处理组(1.5 g/kg GABA)。每周测量血糖。用 Western 印迹法评估蛋白质表达。用 H&E 和 Masson 染色法检测组织病理学变化:-结果:糖尿病大鼠胃组织中的 NOS1 表达水平降低,COX-2 和胰蛋白酶-1 蛋白表达水平升高。胰岛素和 GABA 治疗使 NOS1 和 COX-2 水平恢复到控制值。胰岛素治疗增加了糖尿病大鼠体内的 PI3K、Akt 和 p-Akt,降低了胰蛋白酶-1、PAR-1、PAR-2 和 PAR-3 的水平。胰岛素和 GABA 治疗后,GABAA 和 GABAB 受体水平恢复正常。结论:这些结果表明,GABA 通过作用于 GABA 受体可调节胰蛋白酶-1/PARs/Akt/COX-2 途径,从而改善糖尿病胃肠病的并发症。
{"title":"Long-term GABA Supplementation Regulates Diabetic Gastroenteropathy through GABA Receptor/trypsin-1/PARs/Akt/COX-2 Axis.","authors":"Farzaneh Yazdanimoghaddam, Hossein Rezazadeh, Nepton Soltani, Nasrin Mehranfard, Azadesadat Hosseini Dastgerdi, Mahtab Ghanbari Rad, Maedeh Ghasemi","doi":"10.1134/S1607672924600386","DOIUrl":"https://doi.org/10.1134/S1607672924600386","url":null,"abstract":"<p><strong>Aim: </strong>Molecular alterations of diabetic gastroenteropathy are poorly identified. This study investigates the effects of prolonged GABA supplementation on key protein expression levels of trypsin-1, PAR-1, PAR-2, PAR-3, PI3K, Akt, COX-2, GABAA, and GABAB receptors in the gastric tissue of type 2 diabetic rats (T2DM).</p><p><strong>Method: </strong>-To induce T2DM, a 3-month high-fat diet and 35 mg/kg of streptozotocin was used. Twenty-four male Wistar rats were divided into 4 groups: (1) control, (2) T2DM, (3) insulin-treated (2.5 U/kg), and (4) GABA-treated (1.5 g/kg GABA). Blood glucose was measured weekly. The protein expressions were assessed using western blotting. Histopathological changes were examined by H&E and Masson's staining.</p><p><strong>Results: </strong>-Diabetic rats show reduced NOS1 and elevated COX-2 and trypsin-1 protein expression levels in gastric tissue. Insulin and GABA therapy restored the NOS1 and COX-2 levels to control values. Insulin treatment increased PI3K, Akt, and p-Akt and, decreased trypsin-1, PAR-1, PAR-2, and PAR-3 levels in the diabetic rats. Levels of GABAA and GABAB receptors normalized following insulin and GABA therapy. H&E staining indicated an increase in mucin secretion following GABA treatment.</p><p><strong>Conclusion: </strong>-These results suggest that GABA by acting on GABA receptors may regulate the trypsin-1/PARs/Akt/COX-2 pathway and thereby improve complications of diabetic gastroenteropathy.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR. 利维利单抗与甲氨蝶呤联用对活动性类风湿性关节炎患者的疗效和安全性:SOLAR.III 期随机双盲安慰剂对照试验 56 周的结果
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924701072
V I Mazurov, E L Nasonov, A M Lila, M A Korolev, A M Prystrom, E V Kundzer, N F Soroka, A A Kastanayan, T V Povarova, T V Plaksina, O V Antipova, D G Krechikova, S A Smakotina, O A Tciupa, E V Puntus, T A Raskina, L N Shilova, T V Kropotina, O B Nesmeyanova, T A Popova, I B Vinogradova, E A Dokukina, A V Plotnikova, P S Pukhtinskaia, A V Zinkina-Orikhan, Yu N Linkova, A V Eremeeva, A A Lutckii
<p><p>. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here, we present 1-year efficacy and safety data of the SOLAR study.</p><p><strong>Objectives: </strong>. To evaluate the efficacy and safety of levilimab in combination with methotrexate (MTX) in subjects with MTX resistant active RA.</p><p><strong>Materials and methods: </strong>: The study was conducted at 21 clinical sites in Russia and Belarus. All randomized subjects have completed the study between November 2019 and October 2021. Adult subjects (154) aged ≥18 years with confirmed diagnosis of RA<sup>1</sup> were randomly assigned (2 : 1) to receive either levilimab (162 mg, SC, QW) + MTX (n = 102) or placebo + MTX (n = 52). After W24 of the study all subjects continued to  receive open label levilimab. Subjects who have achieved DAS28-CRP ≤ 2.6 at W24 were switched to maintenance (Q2W) regimen of levilimab at W28 (LVL QW/Q2W and PBO/LVL Q2W arms). Those with DAS28-CRP > 2.6 at W28 continued with QW regimen (LVL QW and PBO/LVL QW arm). The PBO/LVL Q2W arm contained only one subject, thus not included in the analysis. The efficacy analysis was performed in a population of all randomized subjects. Those with missing data due to study discontinuation or rescue therapy prescription were considered non-responders. Otherwise, the analysis was performed on complete cases. Safety was assessed through monitoring of adverse events (AEs) in a population of those, who received at least on dose of LVL (n = 152).</p><p><strong>Results: </strong>: Better response to treatment was observed in LVL QW/Q2W as it composed of those who reach DAS28-CRP ≤ 2.6 at W24. At this time point 15/27 (55.6%) of them achieved ACR70; 23/27 (85.2%) achieved DAS28-CRP remission (<2.6) and 7/27 (25.9%) achieved ACR/EULAR2011 remission of RA. After switching to LVL Q2W, rates of ACR70 and DAS28-CRP<2.6 did not significantly changed until W52: 17/27 (63.0%) and 21/27 (77.8%), respectively, yet the proportion of subject with ACR/EULAR 2011 remission further increased and reached 12/27 (44.4%). LVL QW arm was diminished by subjects who achieved high response to treatment at W24 and composed LVL QW/Q2W arm. Thus, ACR70, and remissions rate in this arm was close to zero at W24. However, continuation of LVL QW in those who not achieved DAS28-CRP ≤ 2.6 at W24 induced ACR70 response in 37/75 (36.0%), DAS28-CRP remission in 35/75 (46.7%) and ACR/EULAR 2011 remission in 8/75 (10.7%) at W52. The most common adverse events (reported in ≥5% of subjects) were blood cholesterol increase (30.3%), ALT increase (23.0%), lymphocyte count decrease (17.1%), ANC decrease (16.4%), blood triglycerides increase (13.8%), bilirubin increase (11.2%), AST increase (9.9%), WBC decrease (9.9%), IGRA with Mycobacterium tuberculosis antigen positive (7.2%), and injection site reactions (
.在此之前,针对活动性类风湿性关节炎(RA)受试者的左利单抗Ⅲ期双盲、安慰剂对照随机临床研究(SOLAR)的24周结果证明,左利单抗优于安慰剂。在此,我们将介绍 SOLAR 研究的 1 年疗效和安全性数据。评估左利单抗联合甲氨蝶呤(MTX)治疗对 MTX 耐药的活动性 RA 受试者的疗效和安全性:研究在俄罗斯和白俄罗斯的 21 个临床研究机构进行。所有随机受试者均在 2019 年 11 月至 2021 年 10 月期间完成了研究。年龄≥18岁、确诊为RA1的成年受试者(154名)被随机分配(2:1)接受左利单抗(162毫克,SC,QW)+MTX(n = 102)或安慰剂+MTX(n = 52)。研究W24结束后,所有受试者继续接受开放标签的左利单抗治疗。W24时DAS28-CRP≤2.6的受试者在W28时转为左利单抗维持治疗(Q2W)方案(LVL QW/Q2W和PBO/LVL Q2W两组)。W28时DAS28-CRP>2.6的患者继续采用QW方案(LVL QW和PBO/LVL QW臂)。PBO/LVL Q2W治疗组只有一名受试者,因此未纳入分析。疗效分析在所有随机受试者群体中进行。因中止研究或开具抢救治疗处方而导致数据缺失的受试者被视为无应答者。否则,将对完整病例进行分析。通过监测至少接受过一次LVL治疗的受试者(n = 152)的不良事件(AEs)来评估安全性:在LVL QW/Q2W中观察到了更好的治疗反应,因为在W24时DAS28-CRP≤2.6。在此时间点,15/27(55.6%)人达到 ACR70;23/27(85.2%)人达到 DAS28-CRP 缓解(结论:......):开放标签期证实了左旋利莫单抗联合MTX对MTX耐药的活动性RA受试者的持久疗效和安全性,并建议在第24周达到RA缓解的受试者转为左旋利莫单抗维持治疗方案(每两周一次)(Q2W)。
{"title":"Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.","authors":"V I Mazurov, E L Nasonov, A M Lila, M A Korolev, A M Prystrom, E V Kundzer, N F Soroka, A A Kastanayan, T V Povarova, T V Plaksina, O V Antipova, D G Krechikova, S A Smakotina, O A Tciupa, E V Puntus, T A Raskina, L N Shilova, T V Kropotina, O B Nesmeyanova, T A Popova, I B Vinogradova, E A Dokukina, A V Plotnikova, P S Pukhtinskaia, A V Zinkina-Orikhan, Yu N Linkova, A V Eremeeva, A A Lutckii","doi":"10.1134/S1607672924701072","DOIUrl":"https://doi.org/10.1134/S1607672924701072","url":null,"abstract":"&lt;p&gt;&lt;p&gt;. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here, we present 1-year efficacy and safety data of the SOLAR study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;. To evaluate the efficacy and safety of levilimab in combination with methotrexate (MTX) in subjects with MTX resistant active RA.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;: The study was conducted at 21 clinical sites in Russia and Belarus. All randomized subjects have completed the study between November 2019 and October 2021. Adult subjects (154) aged ≥18 years with confirmed diagnosis of RA&lt;sup&gt;1&lt;/sup&gt; were randomly assigned (2 : 1) to receive either levilimab (162 mg, SC, QW) + MTX (n = 102) or placebo + MTX (n = 52). After W24 of the study all subjects continued to  receive open label levilimab. Subjects who have achieved DAS28-CRP ≤ 2.6 at W24 were switched to maintenance (Q2W) regimen of levilimab at W28 (LVL QW/Q2W and PBO/LVL Q2W arms). Those with DAS28-CRP &gt; 2.6 at W28 continued with QW regimen (LVL QW and PBO/LVL QW arm). The PBO/LVL Q2W arm contained only one subject, thus not included in the analysis. The efficacy analysis was performed in a population of all randomized subjects. Those with missing data due to study discontinuation or rescue therapy prescription were considered non-responders. Otherwise, the analysis was performed on complete cases. Safety was assessed through monitoring of adverse events (AEs) in a population of those, who received at least on dose of LVL (n = 152).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;: Better response to treatment was observed in LVL QW/Q2W as it composed of those who reach DAS28-CRP ≤ 2.6 at W24. At this time point 15/27 (55.6%) of them achieved ACR70; 23/27 (85.2%) achieved DAS28-CRP remission (&lt;2.6) and 7/27 (25.9%) achieved ACR/EULAR2011 remission of RA. After switching to LVL Q2W, rates of ACR70 and DAS28-CRP&lt;2.6 did not significantly changed until W52: 17/27 (63.0%) and 21/27 (77.8%), respectively, yet the proportion of subject with ACR/EULAR 2011 remission further increased and reached 12/27 (44.4%). LVL QW arm was diminished by subjects who achieved high response to treatment at W24 and composed LVL QW/Q2W arm. Thus, ACR70, and remissions rate in this arm was close to zero at W24. However, continuation of LVL QW in those who not achieved DAS28-CRP ≤ 2.6 at W24 induced ACR70 response in 37/75 (36.0%), DAS28-CRP remission in 35/75 (46.7%) and ACR/EULAR 2011 remission in 8/75 (10.7%) at W52. The most common adverse events (reported in ≥5% of subjects) were blood cholesterol increase (30.3%), ALT increase (23.0%), lymphocyte count decrease (17.1%), ANC decrease (16.4%), blood triglycerides increase (13.8%), bilirubin increase (11.2%), AST increase (9.9%), WBC decrease (9.9%), IGRA with Mycobacterium tuberculosis antigen positive (7.2%), and injection site reactions (","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error-Prone DNA Synthesis on Click-Ligated Templates. 点击连接模板上的无差错 DNA 合成。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600416
A V Endutkin, A O Yakovlev, T D Zharkov, V M Golyshev, A V Yudkina, D O Zharkov

Click ligation is a technology of joining DNA fragments based on azide-alkyne cycloaddition. In the most common variant, click ligation introduces a 4-methyl-1,2,3-triazole (trz) group instead of the phosphodiester bond between two adjacent nucleosides. While this linkage is believed to be biocompatible, little is known about the possibility of its recognition by DNA repair systems or its potential for DNA polymerase stalling and miscoding. Here we report that trz linkage is resistant to several human and bacterial endonucleases involved in DNA repair. At the same time, it strongly blocks some DNA polymerases (Pfu, DNA polymerase β) while allowing bypass by others (phage RB69 polymerase, Klenow fragment). All polymerases, except for DNA polymerase β, showed high frequency of misinsertion at the trz site, incorporating dAMP instead of the next complementary nucleotide. Thus, click ligation can be expected to produce a large amount of errors if used in custom gene synthesis.

单击连接是一种基于叠氮-炔环化连接 DNA 片段的技术。在最常见的变体中,单击连接引入了一个 4-甲基-1,2,3-三唑(trz)基团,而不是相邻两个核苷之间的磷酸二酯键。虽然这种连接被认为具有生物相容性,但人们对其被 DNA 修复系统识别的可能性或其导致 DNA 聚合酶停滞和误码的可能性知之甚少。在这里,我们报告了 trz 连接对参与 DNA 修复的几种人类和细菌内切酶具有抗性。同时,它还能强烈阻断某些 DNA 聚合酶(Pfu、DNA 聚合酶 β),而允许其他聚合酶(噬菌体 RB69 聚合酶、Klenow 片段)绕过。除 DNA 聚合酶 β 外,所有聚合酶在 trz 位点上都出现了高频率的误插入,插入的是 dAMP 而不是下一个互补核苷酸。因此,如果在定制基因合成中使用单击连接,预计会产生大量错误。
{"title":"Error-Prone DNA Synthesis on Click-Ligated Templates.","authors":"A V Endutkin, A O Yakovlev, T D Zharkov, V M Golyshev, A V Yudkina, D O Zharkov","doi":"10.1134/S1607672924600416","DOIUrl":"https://doi.org/10.1134/S1607672924600416","url":null,"abstract":"<p><p>Click ligation is a technology of joining DNA fragments based on azide-alkyne cycloaddition. In the most common variant, click ligation introduces a 4-methyl-1,2,3-triazole (trz) group instead of the phosphodiester bond between two adjacent nucleosides. While this linkage is believed to be biocompatible, little is known about the possibility of its recognition by DNA repair systems or its potential for DNA polymerase stalling and miscoding. Here we report that trz linkage is resistant to several human and bacterial endonucleases involved in DNA repair. At the same time, it strongly blocks some DNA polymerases (Pfu, DNA polymerase β) while allowing bypass by others (phage RB69 polymerase, Klenow fragment). All polymerases, except for DNA polymerase β, showed high frequency of misinsertion at the trz site, incorporating dAMP instead of the next complementary nucleotide. Thus, click ligation can be expected to produce a large amount of errors if used in custom gene synthesis.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Astilbin Induces Apoptosis in Oral Squamous Cell Carcinoma through p53 Reactivation and Mdm-2 Inhibition. 阿斯替滨通过 p53 重激活和 Mdm-2 抑制诱导口腔鳞状细胞癌细胞凋亡
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600374
Aimin Wu, Chungang Zhao

Oral squamous cell carcinoma (OSCC) is a frequently occurring malignancy in the head and neck region. The most commonly mutated gene in OSCC is the tumor suppressor gene p53 (TP53), linked to lower survival and treatment resistance in OSCC patients. Astilbin is a flavonoid amongst several herbal treatments with a variety of pharmacological actions mainly including antioxidant, anti-inflammatory, and anti-cancer characteristics. This study evaluated the effects of astilbin on proliferation of OSCC cell lines SCC90 and SCC4 (bearing a p53 mutation) in relevance to p53 and Mdm-2 pathways. Astilbin inhibited the proliferation of SCC4 and SCC90 cells in a dose- and time-dependent manner. The IC50 values for both the cell lines were about 75 μM for astilbin. A p53 activator (RITA) was used to determine the effects of astilbin on p53 activity, and the results demonstrated synergistic reduction in cell growth. However, when combined with pifithrin-α (a p53 inhibitor), astilbin demonstrated a strong inhibition of its response. Astilbin reduced the mitochondrial membrane potential in SCC4 cells, which is a sign of apoptotic activity. Astilbin decreased the amounts of Mdm-2 (negative regulator of p53) and increased the expression of the p53 gene and protein. In a p53-dependent manner, astilbin suppressed the ability of SCC4 cells to form colonies and heal wounds. This was followed by the induction of mitochondrial intrinsic apoptosis via the activation of caspases 9 and 3, cleavage of PARP, and the suppression of pro-apoptotic Bid. Astilbin-induced p53-mediated apoptosis in OSCC cells as herbal medicinal ingredients.

口腔鳞状细胞癌(OSCC)是头颈部常见的恶性肿瘤。OSCC中最常见的突变基因是抑癌基因p53(TP53),它与OSCC患者的低生存率和耐药性有关。黄芪是多种中草药中的一种黄酮类化合物,具有多种药理作用,主要包括抗氧化、抗炎和抗癌特性。本研究评估了天人菊素对 OSCC 细胞株 SCC90 和 SCC4(带有 p53 突变)增殖的影响,这与 p53 和 Mdm-2 通路有关。芪蛭素以剂量和时间依赖性的方式抑制了SCC4和SCC90细胞的增殖。两种细胞株的芪醇素 IC50 值均为 75 μM 左右。为了确定芪蛭素对 p53 活性的影响,我们使用了一种 p53 激活剂(RITA)。然而,当与 pifithrin-α(一种 p53 抑制剂)结合使用时,芪蛭素会对其反应产生强烈的抑制作用。芪醇素降低了 SCC4 细胞的线粒体膜电位,而线粒体膜电位是细胞凋亡的标志。芪醇素降低了 Mdm-2(p53 的负调控因子)的含量,并增加了 p53 基因和蛋白的表达。通过 p53 依赖性方式,芪醇素抑制了 SCC4 细胞形成菌落和愈合伤口的能力。随后,通过激活 caspases 9 和 3、PARP 的裂解以及抑制促凋亡 Bid,诱导线粒体内在凋亡。作为中药成分,天人菊素诱导 p53 介导的 OSCC 细胞凋亡。
{"title":"Astilbin Induces Apoptosis in Oral Squamous Cell Carcinoma through p53 Reactivation and Mdm-2 Inhibition.","authors":"Aimin Wu, Chungang Zhao","doi":"10.1134/S1607672924600374","DOIUrl":"https://doi.org/10.1134/S1607672924600374","url":null,"abstract":"<p><p>Oral squamous cell carcinoma (OSCC) is a frequently occurring malignancy in the head and neck region. The most commonly mutated gene in OSCC is the tumor suppressor gene p53 (TP53), linked to lower survival and treatment resistance in OSCC patients. Astilbin is a flavonoid amongst several herbal treatments with a variety of pharmacological actions mainly including antioxidant, anti-inflammatory, and anti-cancer characteristics. This study evaluated the effects of astilbin on proliferation of OSCC cell lines SCC90 and SCC4 (bearing a p53 mutation) in relevance to p53 and Mdm-2 pathways. Astilbin inhibited the proliferation of SCC4 and SCC90 cells in a dose- and time-dependent manner. The IC50 values for both the cell lines were about 75 μM for astilbin. A p53 activator (RITA) was used to determine the effects of astilbin on p53 activity, and the results demonstrated synergistic reduction in cell growth. However, when combined with pifithrin-α (a p53 inhibitor), astilbin demonstrated a strong inhibition of its response. Astilbin reduced the mitochondrial membrane potential in SCC4 cells, which is a sign of apoptotic activity. Astilbin decreased the amounts of Mdm-2 (negative regulator of p53) and increased the expression of the p53 gene and protein. In a p53-dependent manner, astilbin suppressed the ability of SCC4 cells to form colonies and heal wounds. This was followed by the induction of mitochondrial intrinsic apoptosis via the activation of caspases 9 and 3, cleavage of PARP, and the suppression of pro-apoptotic Bid. Astilbin-induced p53-mediated apoptosis in OSCC cells as herbal medicinal ingredients.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xmas-2 Protein, the Core Protein of the TREX-2 mRNA Export Complex, Does not Determine the Specificity of ras2 mRNA Binding by the Complex. TREX-2 mRNA导出复合体的核心蛋白 Xmas-2 蛋白并不决定该复合体与 ras2 mRNA 结合的特异性。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600519
M M Kurshakova, Y A Vdovina, S G Georgieva, D V Kopytova

The TREX-2 complex of eukaryotes is responsible for the export of a wide range of mRNAs from the nucleus to the cytoplasm. Previously, we showed that a subunit of the D. melanogaster TREX-2 complex, the PCID2 protein, has a domain that specifically interacts with RNA. However, it remains unknown whether other components of the complex are involved in interaction with and recognition of the target mRNA. In the present study, we determined the role of Xmas-2, the core structural subunit of the complex, in the specific recognition of ras2 mRNA fragments. In this work, we showed that Xmas-2 interacts with ras2 mRNA independently of other subunits of the complex. We showed that RNA-binding domains are located in both the N-terminal domain and the C-terminal domain of Xmas-2. However, the interaction of the protein with ras2 mRNA fragments is independent of RNA sequence and structure and is nonspecific. Thus, the Xmas-2 subunit is not involved in the recognition of specific RNA sequences by the complex.

真核生物的 TREX-2 复合物负责将多种 mRNA 从细胞核输出到细胞质。此前,我们曾发现黑腹蝇 TREX-2 复合物的一个亚基--PCID2 蛋白--具有一个能与 RNA 特异性相互作用的结构域。然而,该复合体的其他成分是否参与了与目标 mRNA 的相互作用和识别,目前仍不得而知。在本研究中,我们确定了该复合体的核心结构亚基 Xmas-2 在特异性识别 ras2 mRNA 片段中的作用。在这项工作中,我们发现 Xmas-2 与 ras2 mRNA 的相互作用独立于复合体的其他亚基。我们发现 RNA 结合结构域位于 Xmas-2 的 N 端结构域和 C 端结构域。然而,该蛋白与 ras2 mRNA 片段的相互作用与 RNA 序列和结构无关,而且是非特异性的。因此,Xmas-2 亚基并不参与复合体对特定 RNA 序列的识别。
{"title":"Xmas-2 Protein, the Core Protein of the TREX-2 mRNA Export Complex, Does not Determine the Specificity of ras2 mRNA Binding by the Complex.","authors":"M M Kurshakova, Y A Vdovina, S G Georgieva, D V Kopytova","doi":"10.1134/S1607672924600519","DOIUrl":"https://doi.org/10.1134/S1607672924600519","url":null,"abstract":"<p><p>The TREX-2 complex of eukaryotes is responsible for the export of a wide range of mRNAs from the nucleus to the cytoplasm. Previously, we showed that a subunit of the D. melanogaster TREX-2 complex, the PCID2 protein, has a domain that specifically interacts with RNA. However, it remains unknown whether other components of the complex are involved in interaction with and recognition of the target mRNA. In the present study, we determined the role of Xmas-2, the core structural subunit of the complex, in the specific recognition of ras2 mRNA fragments. In this work, we showed that Xmas-2 interacts with ras2 mRNA independently of other subunits of the complex. We showed that RNA-binding domains are located in both the N-terminal domain and the C-terminal domain of Xmas-2. However, the interaction of the protein with ras2 mRNA fragments is independent of RNA sequence and structure and is nonspecific. Thus, the Xmas-2 subunit is not involved in the recognition of specific RNA sequences by the complex.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study. 奈达单抗治疗强直性脊柱炎患者的实际保留率、有效性和安全性:LIBRA注册后安全性研究的第一年结果。
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924701084
Sh Erdes, V I Mazurov, I Z Gaydukova, O N Anoshenkova, I B Vinogradova, Yu Yu Grabovetskaya, S Y Davidian, N A Kiryukhina, O E Epifanova, L V Masneva, L V Menshikova, O N Mironenko, N E Nikulenkova, T V Povarova, A N Poliatika, R R Samigullina, A E Sizikov, I N Totrov, I F Umnova, J V Usacheva, A L Chudinov

Netakimab has shown high efficacy in controlled clinical trials in the treatment of AS patients. This article presents results of an observational study of netakimab using in routine clinical practice.

Objective: : To evaluate retention rates and safety of netakimab in patients with AS in real-world clinical practice. Additionally, the efficacy of netakimab was evaluated at 1-year follow-up.

Materials and methods: : Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, and 52 weeks of therapy were collected within the study. Drug survival rate was calculated according to Kaplan-Meier analysis.

Results: : The study included 137 (93 men and 44 women) patients with AS. The average age of patients was 42.3 (11.9) years, 34.3% of patients had previously received therapy with bDMARD, mainly TNF inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% (95% CI, 85.4-95.7) of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; AEs, related to therapy according to the investigator's opinion, were reported in 7 (5.1%) patients. Two patients stopped taking netakimab due to AEs (terminal ileitis and chronic colitis).

Conclusions: : In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.

奈达单抗在治疗强直性脊柱炎患者的对照临床试验中显示出很高的疗效。本文介绍了在常规临床实践中使用奈达单抗的观察性研究结果:目的:评估在实际临床实践中使用奈达单抗治疗强直性脊柱炎患者的保留率和安全性。此外,还对奈达单抗在1年随访中的疗效进行了评估:2020 年 8 月至 2021 年 12 月期间,在俄罗斯联邦的 23 个中心招募患者参与研究。研究对象包括入组前已接受奈达单抗治疗的患者,因此首次就诊的临床和病史数据以回顾性方式录入,并在研究范围内收集治疗 12 周、24 周和 52 周的后续就诊数据。根据卡普兰-梅耶尔分析法计算药物存活率:研究纳入了 137 名(男性 93 名,女性 44 名)强直性脊柱炎患者。患者平均年龄为42.3(11.9)岁,34.3%的患者曾接受过bDMARD治疗,主要是TNF抑制剂。在分析期结束时(治疗 52 周),90.4%(95% CI,85.4-95.7)的患者继续接受奈达单抗治疗。在所有时间点,BASDAI和ASDAS-CRP的评分与基线相比均有统计学意义上的显著下降。患者对奈达单抗的耐受性良好;根据研究者的意见,7 例(5.1%)患者出现了与治疗相关的 AE。两名患者因不良反应(末端回肠炎和慢性结肠炎)而停止服用奈达单抗:在真实世界的临床实践中,奈达单抗的保留率很高,安全性良好,在第一年的治疗中疗效持续。
{"title":"Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: First Year Results of the LIBRA Post-Registration Safety Study.","authors":"Sh Erdes, V I Mazurov, I Z Gaydukova, O N Anoshenkova, I B Vinogradova, Yu Yu Grabovetskaya, S Y Davidian, N A Kiryukhina, O E Epifanova, L V Masneva, L V Menshikova, O N Mironenko, N E Nikulenkova, T V Povarova, A N Poliatika, R R Samigullina, A E Sizikov, I N Totrov, I F Umnova, J V Usacheva, A L Chudinov","doi":"10.1134/S1607672924701084","DOIUrl":"https://doi.org/10.1134/S1607672924701084","url":null,"abstract":"<p><p>Netakimab has shown high efficacy in controlled clinical trials in the treatment of AS patients. This article presents results of an observational study of netakimab using in routine clinical practice.</p><p><strong>Objective: </strong>: To evaluate retention rates and safety of netakimab in patients with AS in real-world clinical practice. Additionally, the efficacy of netakimab was evaluated at 1-year follow-up.</p><p><strong>Materials and methods: </strong>: Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, and 52 weeks of therapy were collected within the study. Drug survival rate was calculated according to Kaplan-Meier analysis.</p><p><strong>Results: </strong>: The study included 137 (93 men and 44 women) patients with AS. The average age of patients was 42.3 (11.9) years, 34.3% of patients had previously received therapy with bDMARD, mainly TNF inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% (95% CI, 85.4-95.7) of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; AEs, related to therapy according to the investigator's opinion, were reported in 7 (5.1%) patients. Two patients stopped taking netakimab due to AEs (terminal ileitis and chronic colitis).</p><p><strong>Conclusions: </strong>: In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circadian Regulation of Expression of Carotenoid Metabolism Genes (PSY2, LCYE, CrtRB1, and NCED1) in Leaves of Tomato Solanum lycopersicum L. 番茄叶中类胡萝卜素代谢基因(PSY2、LCYE、CrtRB1 和 NCED1)表达的昼夜节律调控
IF 0.8 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-08-28 DOI: 10.1134/S1607672924600611
M A Filyushin, A V Shchennikova, E Z Kochieva

The circadian dynamics of the expression of key genes of carotenoid metabolism (PSY2, LCYE, CrtRB1, and NCED1) in the photosynthetic tissue of tomato Solanum lycopersicum L. (cultivar Korneevsky) plants was characterized. An in silico analysis of the gene expression pattern was carried out and a high level of their transcripts was detected in the leaf tissue. qRT-PCR analysis of gene expression was performed at six time points during the day and showed the highest levels of PSY2, LCYE, and NCED1 transcripts in the second half of the light phase and CrtRB1 at the end of the dark phase. The content and composition of carotenoids in leaf tissue in the middle of the day was determined; it was shown that the leaf accumulates 1.5 times more compounds of the ɛ/β-branch of carotenoid biosynthesis pathway than compounds of the β/β-branch.

研究了类胡萝卜素代谢关键基因(PSY2、LCYE、CrtRB1 和 NCED1)在番茄 Solanum lycopersicum L. (栽培品种 Korneevsky)植株光合组织中的昼夜节律表达动态。在一天中的六个时间点对基因表达进行了 qRT-PCR 分析,结果表明 PSY2、LCYE 和 NCED1 的转录物在光照阶段的后半期含量最高,而 CrtRB1 则在暗光阶段的末期含量最高。测定了一天中叶片组织中类胡萝卜素的含量和组成;结果表明,叶片中类胡萝卜素生物合成途径ɛ/β分支化合物的积累量是β/β分支化合物的 1.5 倍。
{"title":"Circadian Regulation of Expression of Carotenoid Metabolism Genes (PSY2, LCYE, CrtRB1, and NCED1) in Leaves of Tomato Solanum lycopersicum L.","authors":"M A Filyushin, A V Shchennikova, E Z Kochieva","doi":"10.1134/S1607672924600611","DOIUrl":"https://doi.org/10.1134/S1607672924600611","url":null,"abstract":"<p><p>The circadian dynamics of the expression of key genes of carotenoid metabolism (PSY2, LCYE, CrtRB1, and NCED1) in the photosynthetic tissue of tomato Solanum lycopersicum L. (cultivar Korneevsky) plants was characterized. An in silico analysis of the gene expression pattern was carried out and a high level of their transcripts was detected in the leaf tissue. qRT-PCR analysis of gene expression was performed at six time points during the day and showed the highest levels of PSY2, LCYE, and NCED1 transcripts in the second half of the light phase and CrtRB1 at the end of the dark phase. The content and composition of carotenoids in leaf tissue in the middle of the day was determined; it was shown that the leaf accumulates 1.5 times more compounds of the ɛ/β-branch of carotenoid biosynthesis pathway than compounds of the β/β-branch.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Doklady Biochemistry and Biophysics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1